SPPI-Board zu Satraplatin-Deal

Seite 1 von 1
neuester Beitrag: 01.07.04 12:44
eröffnet am: 01.07.04 12:44 von: ipollit Anzahl Beiträge: 1
neuester Beitrag: 01.07.04 12:44 von: ipollit Leser gesamt: 683
davon Heute: 1
bewertet mit 0 Sternen

01.07.04 12:44

749 Postings, 6354 Tage ipollitSPPI-Board zu Satraplatin-Deal

GPC Biotech is in talks with several pharma companies to find a marketing partner for Satraplatin. The inside track is probably BMY. They have stated that they will likely finalize any deal before the PIII trial is completed in late 2005. Raj has stated that SPPI will get a share of any up-front payments received as a result of any such deal. This payment could be significant when you consider how much other oncology drugs with several USD 100MM in annual revenue have been out-licensed for. For example, consider that PFE just paid AVE USD 620MM for its oncology drug that currently generated USD 321MM in annual revenue in 2003, & there are many other recent examples along these lines.


Das sehe ich anders... vor Ende der Phase III wird es keinen Deal geben, es sei denn er würde den Campto Deal noch übertreffen:

Associated Press
Pfizer Agrees to Buy Aventis Cancer Drug
Friday June 25, 4:39 pm ET
By Laurence Frost, AP Business Writer  
Pfizer Agrees to Buy Aventis Cancer Drug for  USD620 Million

PARIS (AP) -- The drug maker Pfizer Inc. has agreed to buy Aventis SA's cancer drug Campto for USD 620 million once Sanofi-Synthelabo SA completes its takeover of Aventis, Sanofi said Friday.
Antitrust authorities reviewing Sanofi's agreement to acquire its Franco-German rival to create a new French drug giant requested the Campto sale, Sanofi said.

New York-based Pfizer will first acquire U.S. patent rights for the colorectal cancer treatment and will also take over ongoing clinical trials of the drug.

Pfizer already markets Campto in the United States, in partnership with Aventis.

Separate European antitrust approval will be needed for the second stage of the deal, in which Pfizer would take control of remaining Campto assets, including patents for Europe, Africa and Asia -- where Aventis currently markets the drug.

Aventis generated revenue of 264 million euros (USD 321 million) on its own sales of Campto in 2003, the Sanofi statement said.

Sanofi earlier this week postponed the closing of its cash-and-share offer for Aventis until July 30, a month later than originally planned, after the U.S. Federal Trade Commission said it needed more time to study the deal.

Sanofi chairman Jean-Francois Dehecq said Tuesday he was confident the deal would receive FTC approval before the new closure date.

Pfizer shares fell 99 cents to close at USD 33.82 Friday on the New York Stock Exchange


Pfizer zahlt 620 Mio USD für Campto zu dem Aventis sagt:

Strategic products and late-stage compounds
2003 sales # Peak sales potential

Taxotere: World?s leading chemotherapy agent # EUR 1,362 million # > EUR 3 billion
Campto: A proven market leader # EUR 264 million # > EUR 800 million
Genasense: Aiming to modernize cancer treatment # - # > EUR 2 billion

Das Potential von Campto sieht Aventis bei über 800 Mio EUR. Sie mussten es aber nach der Fusion mit Sanofi verkaufen, da es das Kokurrenzprodukt von Sanofis Oxaliplatin ist, welches peak sales von über 1,5 Mrd USD erzielen soll und wie Satraplatin ebenfalls ein Platinum-Derivat ist.

Taxotere... u.a. 1st-line in HRPC, mögliche peak sales über 3 Mrd. EUR ... GPC startet eine PhaseI Studie Taxotere-Satraplatin-Kombo für mehrere Tumorarten.

mfg ipollit  

   Antwort einfügen - nach oben